Please provide your email address to receive an email when new articles are posted on . Intra-arterial alteplase after successful reperfusion with mechanical thrombectomy for large vessel occlusion ...

Please provide your email address to receive an email when new articles are posted on . In patients with moderate or severe ischemic stroke, a lower dose of IV tenecteplase yielded less favorable ...

LOS ANGELES -- The HOPE trial made another case for extending the therapeutic window for IV thrombolysis in acute ischemic stroke, potentially widening the pool of people eligible for therapy. Among ...

Alteplase at 0.6 mg/kg body weight produces comparable outcomes to the standard 0.9 mg/kg dose in Korean patients with ischaemic stroke, a recent study reveals. Use of low-dose alteplase is common in ...

"This was a pivotal trial in establishing the safety and efficacy of tenecteplase as an alternative to alteplase in the thrombolytic treatment of acute ischemic stroke within 4.5 hours in Asian ...

LOS ANGELES — Not only is tenecteplase a cheaper and more convenient thrombolytic agent than alteplase, but new research suggests it also leads to better outcomes in stroke patients selected for ...

Making the switch from alteplase to tenecteplase for stroke thrombolysis can be done successfully when the appropriate preparations are taken, and it may improve patient outcomes, the experience of a ...

A study concludes that a low-dose of the clot-busting drug—tenecteplase—may be beneficial for eligible stroke patients that do not need an intervention for the mechanical removal of a clot.

Whether the evidence supports wider use of tenecteplase (TNKase; Genentech)—a thrombolytic agent with an indication for acute MI—as an alternative to alteplase (Activase; Genentech) for the treatment ...